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Abstract
The sterol sensor SCAP is a key regulator of SREBP-2, the major transcription factor controlling cholesterol synthesis.
Recently, we showed that there is a global down-regulation of cholesterol synthetic genes, as well as SREBP-2, in the brains
of diabetic mice, leading to a reduction of cholesterol synthesis. We now show that in mouse models of type 1 and type 2
diabetes, this is, in part, the result of a decrease of SCAP. Homozygous disruption of the Scap gene in the brains of mice
causes perinatal lethality associated with microcephaly and gliosis. Mice with haploinsufficiency of Scap in the brain show a
60% reduction of SCAP protein and ,30% reduction in brain cholesterol synthesis, similar to what is observed in diabetic
mice. This results in impaired synaptic transmission, as measured by decreased paired pulse facilitation and long-term
potentiation, and is associated with behavioral and cognitive changes. Thus, reduction of SCAP and the consequent
suppression of cholesterol synthesis in the brain may play an important role in the increased rates of cognitive decline and
Alzheimer disease observed in diabetic states.
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Introduction
The brain is the most cholesterol rich organ in the body,
containing more than 20% of the sterol pool and almost all of the
cholesterol is produced in situ [1]. Multiple in vitro studies have
indicated that cholesterol in the brain is important for synapse
biogenesis and vesicle formation [2,3]. Cholesterol synthesis is a
highly regulated process controlled by the master transcriptional
regulator SREBP-2. SREBP-2 is transcribed and translated into
an inactive precursor that is sequestered in the endoplasmic
reticulum (ER). However, when sterol levels are low, the sterol
sensor SCAP is able to chaperone SREBP-2 to the Golgi
apparatus where it is cleaved to release a transcriptionally active
form that can enter the nucleus [4]. Conversely, in times of sterol
abundance, SCAP is bound by sterols and remains sequestered in
the ER along with the unprocessed SREBP-2 [4].
Diabetes mellitus is a multifactorial disease due to deficient
insulin secretion and/or action, resulting in hyperglycemia,
alterations in lipid metabolism, and a variety of complications in
tissues throughout the body. These complications extend to the
central nervous system (CNS), including cognitive dysfunction and
behavioral changes, and are observed both in type 1 and type 2
diabetes [5]. Studies have shown altered information processing,
psychomotor efficiency, attention, and mental flexibility in type 1
diabetes, whereas type 2 diabetes more often affects memory,
psychomotor speed, and executive function [6]. In addition,
changes have been observed on imaging of the hippocampi of both
type 1 and type 2 diabetics [7,8].
We recently demonstrated that in mouse models of diabetes
there is a broad reduction in the expression of genes in the
cholesterol biosynthetic pathway throughout the brain, resulting in
decreased brain cholesterol synthesis [9]. This is accompanied by
decreased expression of SREBP-2, which is more pronounced at
the protein than the mRNA level [9]. Simultaneous reduction in
cholesterol content and cholesterol biosynthesis suggests that, in
the brain, diabetes causes a defect at the level of the sterol-sensing
molecules, which constitute a negative-feedback system on
SREBP-2 processing and maintenance of cellular cholesterol
content. Here we show that the sterol sensing protein SCAP,
which plays a key role in the post-transcriptional regulation of
SREBP-2, is decreased in the brains of diabetic mice. Brain-
specific heterozygous SCAP knockout mice have reduced levels of
cholesterol genes and exhibit a 30% reduction in brain cholesterol
synthesis, mimicking what is observed in diabetes. This results in
defects at the electrophysiological and cognitive level. Thus,
diabetes results in a reduction of SCAP expression, which
PLOS Biology | www.plosbiology.org 1 April 2013 | Volume 11 | Issue 4 | e1001532contributes to a reduction of brain cholesterol synthesis. Reduction
in SCAP leads to an impairment in neuronal transmission and
cognitive dysfunction that may contribute to the neurological
complications observed in diabetic states.
Results
SCAP Protein Is Reduced in the Brains of Diabetic Mice
Recently we demonstrated that diabetes produces a global
suppression of the enzymes of cholesterol biosynthesis and their
master transcriptional regulator SREBP-2 in the brain; this results
in reduced cholesterol biosynthesis and altered ability of neurons to
form synapses and synaptic vesicles [9]. Since reduction of
cholesterol and its precursors would normally drive a compensatory
increase in SREBP-2 and cholesterol biosynthesis, we speculated
that sterol-sensing might be impaired in the brains of diabetic mice.
SCAP, a binding partner and a chaperone protein of SREBP-2,
plays an essential role in sterol feedback regulation, serving as the
major sterol-sensing molecule [4]. Western blotting of extracts of
brains from streptozotocin (STZ)-treated mice (a model of type 1
diabetes)revealed an ,50% decrease inSCAP protein inthe mouse
cerebral cortex (Figure 1A). This reduction of SCAP protein in the
STZ diabetic mouse was not limited to the cortex and was observed
throughout the brain, with a 33% decrease in the hypothalamus
(Figure 1B) and a 31% decrease in the thalamus (unpublished data).
There is also a significant,butsmaller, reductionof SCAP proteinin
the cerebral cortices of db/db mice (a model of type 2 diabetes),
consistent with a modest down-regulation of genes of the cholesterol
synthesis pathway in the brains of these animals (Figure 1C). The
decrease in Scap mRNA in STZ diabetic mice was completely
rescued by three injections of insulin into the intracerebroven-
tricular (ICV)spaceover the courseof30 h (Figure1D).ICVinsulin
also resulted in a partial rescue of SCAP protein during this short
treatment period (Figure 1E). This occurred with no change in
blood glucose levels [9]. By contrast, there were no changes in Scap
message after treatment of leptin deficient ob/ob mice with leptin
(unpublished data).
Homozygous Deletion of the SCAP gene in the Brain
Causes Perinatal Lethality, Decreased Cholesterol
Content, Microcephaly, and Gliosis
To determine the consequences of reduced SCAP content in the
brain in the absence of diabetes, we created mice with
homozygous and heterozygous loss of SCAP specifically in the
brain by crossing mice carrying a modified Scap gene with LoxP
sites surrounding exon 1 [10] with mice expressing Cre-
recombinase under control of the rat nestin promoter and
enhancer [11]. This results in inactivation of the Scap gene in
both neuronal and glial cells beginning on day e11.5 [11].
Homozygous Scap-ablated embryos (nestin-Cre
+/2:Scap
lox/lox, desig-
nated as N-Scap [2/2]) were obtained at normal Mendelian
frequency; however, all of the homozygous N-Scap (2/2) mice
died immediately after birth on postnatal day 0 (P0). Analysis of
brains of these mice revealed an almost complete (.95%) absence
of Scap mRNA and SCAP protein (Figure 2A and 2B). The N-Scap
(2/2) neonates exhibited almost normal gross morphology, but
had flat skulls and uninflated lungs (Figure 2C). Likewise, when
mice were delivered by Cesarean section on embryonic day 18.5
(E18.5), all of the control (nestin-Cre
2/2:Scap
lox/wt or
nestin-Cre
2/2:Scap
lox/lox) and N-Scap (+/2)( nestin-Cre
+/2:Scap
lox/wt)
littermates initiated breathing, whereas N-Scap (2/2) failed to do
so. The flat skull in N-Scap (2/2) was due to microcephaly; brains
from N-Scap (2/2) mice exhibited an overall reduction in size of
43% by weight compared with those from the control littermates
(50610 mg versus 87.5615 mg in controls, p=0.003) (Figure 2D).
There were no gross morphologic changes in the brain other than
the decrease in size.
Gene expression analysis of the brains of N-Scap (2/2) mice
revealed a pattern consistent with a loss of SCAP activity. Thus,
SREBP-2 (Srebf2) and its downstream genes (Hmgcr, Sqle, Fdps, Idi1,
and Ldlr) were all markedly down-regulated by 70%–90%
(Figure 2E). Expression of the SREBP-1c (Srebf1c) gene was also
reduced by 88%, whereas expression of its downstream genes (Fasn
and Acaca) were only decreased by half (Figure 2E). The reduction
in cholesterol synthetic enzymes was accompanied by a 50%
reduction in total cholesterol content per gram of brain tissue
(2.360.6 versus 4.761.2 mg of cholesterol/mg of brain in controls,
p,0.01) (Figure 2F). In contrast, total brain triglyceride content
was increased in N-Scap (2/2) mice compared to controls
(19.960.4 versus 15.961.7 mmol of triglycerides/mg of brain in
controls, p,0.05) (Figure 2G). Measurement of triglycerides in
adult N-Scap (+/2) brains showed no difference when compared
to controls (26.863.3 versus 27.461.3 mmol of triglycerides/mg of
brain in controls) (Figure 2G).
Homozygous deletion of the Scap gene in the brain also caused
marked changes in brain histology and cell type distribution.
Expression of glial fibrillary acidic protein (Gfap), an astrocyte
marker, was up-regulated by more than 3-fold in the whole brain
of N-Scap (2/2) mice, whereas the microglia marker F4/80 (Emr1)
was reduced by 59% and the neuronal marker MAP-2 (Matp2) was
unchanged (Figure S1). The increase in Gfap mRNA correlated
with a significant increase in GFAP protein in the N-Scap (2/2)
brain (Figure 2H), which was confirmed by immunohistochemistry
showing a robust increase of GFAP- positive fibers in N-Scap
(2/2) brains resulting in a histological picture resembling gliosis
(Figure 2I).
Author Summary
Diabetes is associated with an increased risk of Alzheimer
disease, depression, and cognitive decline, but the causal
link underlying these associations is unclear. We previously
showed that in diabetic mice there is a reduction in brain
synthesis of cholesterol, which is required for normal
formation of synapses between neurons. Here we show
that this deficit is caused, in part, by a reduction in the
levels of SCAP, a protein known to help regulate
cholesterol synthesis by promoting the relocalization,
cleavage, and liberation of the key transcription factor
SREBP2. These changes in cholesterol biosynthesis are
rescued by treatment of the diabetic mice with insulin.
When the level of SCAP in the brains of non-diabetic mice
is lowered by genetic manipulation, there is a decrease in
cholesterol synthesis in the brain, and this results in
impaired signaling between neurons, memory deficits, and
abnormal responses to stress. These findings indicate that
the reduction in SCAP associated with diabetes can
contribute to changes in cognitive function in this disease.
Brain Metabolism and Function in SCAP KO Mice
PLOS Biology | www.plosbiology.org 2 April 2013 | Volume 11 | Issue 4 | e1001532Figure 1. Diabetes reduces SCAP in the brain and is rescued by ICV insulin. Densitometry of the Western blots for SCAP of cytoplasmic
extracts were normalized by the level of b-tubulin as an internal control. (A) Cortex of control and STZ-induced diabetic mice. (B) Hypothalami of
control and STZ-induced diabetic mice. (C) Cortex of db/+ and db/db mice. (D) Scap mRNA expression levels in the hypothalami of control, STZ-
induced diabetic, and STZ-induced diabetic mice treated with insulin. (E) Western blots of SCAP of cytoplasmic extracts, normalized to b-tubulin from
the cortex of control, STZ-induced diabetic, and STZ-induced diabetic treated with ICV insulin, *, p,0.05; ***, p,0.001; #, p,0.05 compared to ICV
insulin group, by t-test.
doi:10.1371/journal.pbio.1001532.g001
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PLOS Biology | www.plosbiology.org 3 April 2013 | Volume 11 | Issue 4 | e1001532Figure 2. CNS-specific homozygous Scap deficient (N-Scap [2/2]) mice exhibit microcephaly and gliosis. (A) Scap mRNA expression
levels in the brains of P0 mice by qPCR, average expression values in Control assigned a value of 1. Bars denote mean 6 SEM. (B) Western blots of
cytoplasmic extracts from brains of control, N-Scap (+/2), and N-Scap (2/2) mice. (C) Appearance of control and N-Scap (2/2) neonates. Dashed
Brain Metabolism and Function in SCAP KO Mice
PLOS Biology | www.plosbiology.org 4 April 2013 | Volume 11 | Issue 4 | e1001532Haploinsufficiency of Scap in the Central Nervous System
Suppresses the SREBP-2 Pathway, In Vivo Cholesterol
Synthesis, and Synapse Formation in the Brain
To better mimic the 50% reduction in SCAP in the brains of
STZ-diabetic mice we characterized mice with haploinsufficiency
of the Scap gene in the brain. qPCR analysis of Scap mRNA in
extracts of brain regions dissected from N-Scap (+/2) mice
revealed an approximately 40% reduction of Scap gene expression
in all parts of the brain examined, including cerebral cortex and
hypothalamus (Figure 3A). By Western blotting of extracts of the
cortex, expression of SCAP protein was reduced slightly more
(60%, when normalized with b-tubulin) in N-Scap (+/2) mice
(Figure 3B).
Previous studies have shown that knockout of the Scap gene in the
liver causes a reduction in the amounts of both the precursor and
the nuclear forms of SREBP-2 and SREBP-1 [10]. We found a
similar significant reduction of both SREBP-2 and SREBP-1
precursors in the cytoplasmic extract of cerebral cortices of N-Scap
(+/2) mice (Figure 3C), as well as a reduction in the mature nuclear
forms of these transcription factors (Figure 3D). This resulted in a
decrease intheexpression of genesdownstream ofSREBP-2(Hmgcr,
Sqle, Idi1, and Ldlr) by 10%–27% in the cerebral cortex and
hypothalamus,aswellassomedecreaseinSrebf2mRNA(Figure3E).
The reduction of squalene epoxidase at the protein level was also
confirmed by Western blotting (Figure 3C). The decrease in
SREBP-1 did not result in a decrease in expression of the
downstream protein fatty acid synthase but did cause a 20%
reduction in acetyl-CoA carboxylase in the N-Scap (+/2) mice.
There were large decreases in these proteins in the N-Scap (2/2)
mice (Figure S2). The reduction in cholesterol synthesis was not
accompanied by a similar decrease in cholesterol catabolism. Levels
of Cyp46a1 mRNA were the same in the cerebral cortices and
hypothalami of control and N-Scap (+/2) mice, and whole brains of
control and N-Scap (2/2) mice (Figure S3).
To determine if the down-regulation of cholesterologenic genes
could affect in vivo cholesterol synthesis, we assessed cholesterol
synthesis in the brains of N-Scap (+/2) mice in vivo using tritiated
water. This revealed a 29% reduction in cholesterol synthesis in
the brains (p,0.05) of N-Scap (+/2) mice (Figure 3F), closely
paralleling the change observed in STZ-diabetic mice [9]. Synapse
marker proteins, including syntaxin-1A (STX1A) and post-synapse
density 95 (PSD95) were also decreased in the N-Scap (+/2) mouse
cerebral cortices (Figure 3G); similar to what has been observed in
STZ-diabetic mice [12]. This occurred with no change in glucose
levels (after a 4-h fast 18266.7 versus 17568 mg/dl in controls) or
fed insulin levels (0.3260.02 versus 0.3360.04 ng/ml in controls).
Thus, the heterozygous N-Scap (+/2) mice mimic the reduction of
SCAP protein, the impaired cholesterol biosynthesis, and the
decrease in synapse markers observed in the brains of diabetic
mice, but without the concomitant changes in glucose or insulin
levels.
Impaired Synaptic Transmission in the Hippocampus of
N-Scap (+/2) Mice
To determine whether changes in cholesterol metabolism
induced by the decrease of brain SCAP protein might alter
synaptic transmission, we performed intracellular and extracellular
electrophysiological recordings from neurons in the area CA1
region of the hippocampus, an area of the brain with
demonstrated abnormalities on imaging in humans with type 1
and type 2 diabetes [7,8]. Intracellular recording of miniature
excitatory postsynaptic current (mEPSC) events were monitored
by continuous voltage-clamp to assess differences in frequency and
amplitude of presynaptic events at CA1 neurons. The basal
frequency of mEPSCs of area CA1 neurons was reduced by more
than 60% in N-Scap (+/2) mice (0.560.1 Hz; n=15 cells; p,0.01)
compared to control mice (1.460.3 Hz; n=15 cells) (Figure 4A
and 4B), but no differences in mEPSC amplitudes were observed
between the two genotypes (control: 8.960.2 pA; N-Scap (+/2):
8.760.1 pA; n=1500 events) (Figure 4C). These results strongly
implicate an effect of SCAP reduction on presynaptic neurotrans-
mitter release, with no differences at the postsynaptic membrane.
To further assess the effect of reduced SCAP levels on synaptic
transmission, we tested the synaptic efficacy of the Schaeffer
collateral pathway between control and N-Scap (+/2) mice via
paired-pulse facilitation and long-term potentiation (LTP). Paired-
pulse facilitation was elicited with interpulse intervals of 50, 100,
150, and 200 ms, and then calculated as the paired-pulse ratio of
field excitatory postsynaptic potential (fEPSP) amplitude elicited by
the second to first test stimuli. The paired-pulse ratio was greatest
when elicited with an interpulse interval of 50 ms and was
significantly reduced in N-Scap (+/2) hippocampal slices (control:
1.7360.08; n=17; N-Scap (+/2): 1.4560.04; n=12; p,0.01)
(Figure 4D and 4E), suggesting significant alterations in synapse
plasticity in N-Scap (+/2) hippocampi. Further studies will be
required to define the mechanism of this defect at the synaptic level.
We also tested the efficacy of neurotransmitter release following
high frequency stimulation to determine if a robust and inducible
LTP can be generated at CA1 synapses of N-Scap (+/2)
hippocampal slices. High frequency stimulation (46100 Hz)
reliably induced a robust and reproducible LTP in hippocampal
slices from both control and N-Scap (+/2) mice. However, the
change in fEPSP slope was markedly reduced in N-Scap (+/2)
slices (Figure 4F and 4G). The mean fEPSP slopes measured 10,
30, 60, and 120 min after LTP induction in control slices were
25561, 18964, 19661, 18861, and 18361, respectively (n=10)
(Figure 4H). All corresponding slope values were significantly
lower in slices from N-Scap (+/2) mice (19863, 14761, 13962,
12762, and 12562, respectively; n=8; p,0.001) (Figure 4H).
Taken together, these findings indicate a significant impairment of
synaptic transmission at CA1 neurons of the hippocampus in the
brains of SCAP heterozygous knockout mice.
N-Scap (+/2) Mice Exhibit Impairment in Recognition of
Novel Objects and Altered Response to Stress
Memory is impaired in patients with type 2 diabetes and to a
lesser extent in patients with type 1 diabetes [13,14]. To assess
memory in our mouse model we used the novel object recognition
test, which takes advantage of the natural bias of preference for
novelty in rodents [15]. As expected, after a training session,
control mice spent significantly more time exploring the novel
object as compared to the training object (16.463 s versus
lines indicate difference in curvature of the skulls. Aerated lungs were visible in the control pups (arrow), whereas N-Scap (2/2) pups did not start
breathing and died soon after birth. (D) Appearances of the brains at E18.5. (E) Comparison of gene expression for the cholesterol synthesis (SREBP-2
pathway) and fatty acid synthesis (SREBP-1 pathway) in brains of Control and N-Scap (2/2) neonates. (F) Total brain cholesterol content normalized
to tissue weight. (G) Total brain triglyceride content normalized to tissue weight in P0 and P65 mice. (H) Western blots of cytoplasmic extracts from
brains of Control, N-Scap (+/2), and N-Scap (2/2) neonates for GFAP protein. (I) Immunohistochemistry for GFAP in P0 brains. Scale bar=25 mm. *,
p,0.05; **, p,0.01; ***, p,0.001 by t-test.
doi:10.1371/journal.pbio.1001532.g002
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object (Figure 5A and 5B). By contrast, N-Scap (+/2) mice failed to
demonstrate any significant preference for the novel object over
the training object (13.862.5 s versus 12.962.1 s), spending
almost identical amounts of time with each object (Figure 5A
and 5B).
Diabetic patients have an increased prevalence of anxiety
disorders [16,17]. We used two different tests to assess anxiety in
the N-Scap (+/2) mice. We performed the elevated open-platform
test, which is used to assess psychological stress [18]. While
controls spent 33.967.7 s in a frozen posture on the open
platform, the N-Scap (+/2) mice exhibited a much shorter
duration of freezing behavior (14.362.7 s, p,0.05) induced by
this stress (Figure 5C). The novelty-suppressed feeding test assesses
the effects of conflicting motivations of the drive to eat food after
fasting and the fear of venturing into a novel arena of white paper
Figure 3. N-Scap (+/2) mice have suppressed cholesterol synthesis leading to a reduction of synapse markers. (A) Scap mRNA
expression levels in brain regions of 11-wk-old control (open bars) and N-Scap (+/2) mice (closed bars) were measured by qPCR, and average
expression values in olfactory bulb from Control littermates assigned a value of 1. (B) Western blots of whole cell extracts from cerebral cortices of 5-
wk-old mice. (C) Protein levels of SREBP precursors and squalene epoxidase (SQLE) in cytoplasmic extracts from cerebral cortices. (D) Cleaved
(transcriptionally active) SREBPs in nuclear extracts from cerebral cortices. CREB is used as an internal control. (E) mRNA expression levels of
cholesterol-related genes in the hypothalami and cortices of 11-wk-old mice. (F) In vivo cholesterol synthesis in the whole cerebrums was assessed for
Control and N-Scap (+/2) mice. (G) Densitometry of Western blots for synapse markers of cytoplasmic extracts from cerebral cortices of 5-wk-old
mice. STX1A, syntaxin 1A; SYP, synaptophysin; PSD95, post-synapse density 95; GFAP, glial fibrillary acidic protein; MBP, myelin basic protein. Values
are normalized to b-tubulin. *, p,0.05; **, p,0.01; ***, p,0.001 by t-test.
doi:10.1371/journal.pbio.1001532.g003
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mice showed a markedly reduced latency to enter the arena
compared to control mice, (17.166.4 versus 61.5619 s, p,0.05)
i.e., were more adventuresome or reckless in their behavior than
controls (Figure 5D). Once they entered the novel area, however,
there was no difference in the latency to start eating the food
pellets (151.2634.1 versus 150.7618.8 s) (Figure 5D), demon-
strating that hunger was not the driver of the reduced latency.
Figure 4. Synaptic transmission is impaired in N-Scap (+/2) mice. (A) Sample traces of mEPSC events at area CA1 neurons. Scale: 20 pA,
500 ms. (B) Basal frequency of mEPSCs at area CA1. (C) Mean amplitude of mEPSCs at area CA1 neurons. (D) Sample traces of a pair of fEPSPs elicited
with an interpulse interval of 50 ms at the Schaeffer collateral pathway. The relative increase in fEPSP amplitude at the second pulse was calculated as
the paired-pulse ratio (P2/P1) in control (a) and N-Scap (+/2) (b) hippocampal slices. Scale: 0.5 mV, 10 ms. (E) Paired-pulse ratios elicited following all
interpulse intervals tested from hippocampal slices. (F) Sample traces of fEPSPs elicited pre- and post-tetanic stimulation (46100 Hz trains) of CA1
synapses from control (c, d) and N-Scap (+/2) (e, f) hippocampal slices. Scale: 0.5 mV, 10 ms. (G) LTP, measured as the percent increase in fEPSP slope
from baseline, achieved in slices from N-Scap (+/2) mice (gray) and controls (black). (H) LTP measured at 10, 30, 60, 90, and 120 min post-tetanus in
CA1 synapses. *, p,0.05; **, p,0.01; ***, p,0.001; ns, not significant.
doi:10.1371/journal.pbio.1001532.g004
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PLOS Biology | www.plosbiology.org 7 April 2013 | Volume 11 | Issue 4 | e1001532Figure 5. N-Scap (+/2) mice exhibit impaired cognitive function and abnormal behavior. (A) Novel object recognition test. Exploration
time for a novel object (open bars) and a familiar object (closed bars) is indicated. **, p,0.01 by t-test. (B) Percentage of duration spent with the novel
object in the same test. **, p,0.01 by t-test. (C) Elevated open platform test. Duration of freezing reaction on a platform during the 5-min test is
Brain Metabolism and Function in SCAP KO Mice
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stress-related hormones corticosterone, epinephrine, and norepi-
nephrine did not differ between control and N-Scap (+/2) mice.
However, when the mice were isolated in individual transport
containers for an hour, there was a robust elevation of stress
hormone levels in N-Scap (+/2) mice compared with control mice
with elevations in corticosterone (1.8-fold) and norepinephrine
(2.2-fold) and a trend towards increased epinephrine (15-fold)
(Figure 5E). The surprising increase in stress hormones in these
mice despite an apparent decrease in anxiety behaviors may
indicate an inappropriate reaction to stress rather than a true
anxiolytic effect.
To further explore the possible relationship between behavior
and the abnormal recordings found in the hippocampi of these
mice we performed two behavioral tests which specifically use
hippocampal function: contextual fear conditioning and the
Morris water maze. In the contextual fear conditioning exper-
iment N-Scap (+/2) mice showed impaired acquisition of the fear
conditioning in response to a foot shock, as demonstrated by a
decrease in freezing (Figure 5F). In addition, on the second day
there was reduced freezing during the first minute in the context
and the first and second minute in the altered context (Figure 5G),
with later time points maintaining the same trend but losing
statistical significance. This testing suggests impairments in
hippocampal functioning, although we cannot rule out the
possibility that there is some difference in pain thresholds
between the mouse genotypes. We also performed a Morris
water maze. We were unable to see significant differences
between the two genotypes in this test though the N-Scap (+/2)
mice showed a trend towards spending more time in the incorrect
quadrants during the probe trials (Figure S4). Similar discordance
between abnormal recordings in the hippocampus and abnor-
malities in the water maze have been previously observed in other
models [20].
Metabolic and Activity Characteristics of N-Scap (+/2)
Mice
Finally, we evaluated feeding behavior and energy expenditure
as measures of hypothalamic function in these mice. The N-Scap
(+/2) mice consumed more food than the control mice, especially
during the dark phase (Figure 6A and 6B). This phenotype is
consistent with mice following SREBP-2 gene silencing in the
hypothalamus shown in our previous study [9]. This correlates
with mildly reduced expression of the anorexigenic neuropeptide
CART (Cartpt), and increased expression of the orexigenic
neuropeptide Agrp in the hypothalamus of the N-Scap (+/2) mice
(Figure 6C). Energy expenditure, as represented by oxygen
consumption in a metabolic cage, was about 20% higher in the
N-Scap (+/2) mice than in control mice (Figure 6D). Consistent
with this, locomotor activity of N-Scap (+/2) mice during this
period indicated a significant, parallel increase (Figure 6E and 6F).
The increase in energy expenditure compensated for the increase
in food intake, resulting in similar body composition (Table S1).
The respiratory exchange ratio (RER) was also high in the N-Scap
(+/2) mice during the first 6 h of the dark cycle (Figure 6G),
suggesting increased utilization of carbohydrate as a fuel.
Discussion
In our previous study we showed that cholesterol synthesis is
significantly impaired in multiple mouse models of diabetes due to
a down-regulation of most of the genes in the cholesterol
biosynthesis pathway [9]. In this study we show that this is due,
at least in part, to a significant reduction of the sterol sensor
protein SCAP in the brains of diabetic mice. Here we have used
genetically modified mice with a defect in cholesterol synthesis to
determine the consequences of decreased brain cholesterol, in the
absence of the hyperglycemia and impaired insulin signaling found
in diabetic mice. Homozygous deletion of Scap in the brain causes
microcephaly, gliosis, and early postnatal lethality. Mice with a
brain-specific Scap heterozygous knockout, on the other hand,
closely mimic the decrease in sterol synthesis observed in the
diabetic brain, and this leads to significant attenuation of synaptic
transmission and cognitive dysfunction, even in the absence of any
systemic metabolic derangement. Because Scap is knocked out
during the prenatal period we cannot rule out a developmental
contribution to the changes observed.
Cholesterol comprises a significant component of the neuronal
membrane and is thus critical for proper neuronal transmission.
Reduction in cholesterol synthesis decreases the formation of
synaptic contacts between neurons [9]. We show here that the
reduction of cholesterol synthesis in the brains of N-Scap (+/2)
mice produces adverse effects on neuronal transmission by
decreasing the efficacy of synaptic transmission. Diabetic rodents
exhibit impaired performance in the novel object recognition test
and contextual fear conditioning test—functional measures of
memory in rodents [21,22]—and this is mimicked in the N-Scap
(+/2) mouse. Impairment of LTP expression in the CA1 region of
the hippocampus in diabetic animals has also been reported [23–
25] and is also seen in the N-Scap (+/2) mouse. The impairment in
LTP provides an electrophysiologic correlate for the impaired
memory observed in the novel object recognition test and the
contextual fear conditioning test. Coupled with our previous
studies showing altered brain cholesterol metabolism in diabetes
[9], the current results provide the first evidence indicating that
failure in regulation of cholesterol homeostasis in the brain may
contribute to the cognitive impairment seen in diabetes (see model
in Figure 7). While the N-Scap heterozygous mouse model system
does not allow for the precise dissection of the relative
contributions of SREBP-2 processing and its effects on cholesterol
synthesis versus SREBP-1 processing and its potential effects on
fatty acid and triglyceride synthesis, it seems likely that SREBP-2
and cholesterol are more important. Although the knockout of
SCAP produces changes to SREBP-1 processing, we find no defect
in free fatty acid synthesis in the brains of N-Scap (+/2) mice
(unpublished data), nor is there a decrease in triglyceride content
in the brain. This is in contrast to a conditional knockout of SCAP
in the liver, which causes decreases in serum free fatty acids and
triglycerides of 46% and 53%, respectively, but only a 24%
decrease in serum cholesterol [10]. This may be explained by the
fact that while cholesterol is unable to cross the blood-brain
barrier, fatty acids and glycerol, the building blocks of triglycer-
ides, are able to pass. While fatty acid and glycerol transport across
the blood-brain barrier may not fully compensate for all of the
indicated. *, p,0.05 by t-test. (D) Novelty-suppressed feeding test. Left panel shows latency to enter the novel arena. Right panel indicates latency to
start eating the food pellets. *, p,0.05 by t-test. (E) Serum concentrations of stress-related hormones, corticosterone (Cort), epinephrine (Epi), and
norepinephrine (NE) were measured under unstressed or stressed (after 1 h in isolation in a mouse transport container) conditions. (F) and (G)
Contextual Fear Conditioning. The percentage of time in a freezing posture was measured at baseline and after shock 1 and 2 on day 1. On day 2, the
percentage of time freezing was measured in both the same container from day 1 (context) and a new container (altered context).*, p,0.05; **,
p,0.01.
doi:10.1371/journal.pbio.1001532.g005
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to significantly mitigate the effects given the normal to increased
triglyceride levels observed in this manuscript. Nonetheless, the
SREBP-1 pathway may have a greater impact in diabetes as there
is a 15% decrease in fatty acid synthesis in brains of STZ diabetic
mice (unpublished data). Further, there is also the possibility that
components of the SREBP-2 pathway beyond what are explored
here, such as isoprenoid production, may be contributing to the
observed phenotype.
Exactly how lowering cellular cholesterol in the brain might
affect brain function is unclear and likely multifactorial. Choles-
terol depletion has been shown to retard or prevent
Figure 6. Feeding behavior and energy expenditure were altered in N-Scap (+/2) mice. (A) Food intake of the 12-wk-old control (n=7)andN-
Scap (+/2)m i c e( n=7) were measured twice a day for 8 consecutive days. (B) Average food intake during light and dark phase. (C) Expression levels of
appetite-related neuropeptide genes in the hypothalami as measured by real time PCR. (D–F) Oxygenconsumption (D), locomotor activity (E), average of
locomotor activity monitored for 3 d (F), and respiratory exchange ratio (RER) (G) were measured by CLAMS. (G) Average of locomotor activity monitored
for 3 d in the CLAMS analysis. Control (n=7, open bars) and N-Scap (+/2)m i c e( n=7, closed bars) were compared. *, p,0.5; **, p,0.01 by t-test.
doi:10.1371/journal.pbio.1001532.g006
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choline receptors [26] and block vesicle biogenesis in neurosecre-
tory cells, consistent with a role for cholesterol in regulating
membrane fluidity and the changes in curvature necessary for full
vesicle formation [2,27]. Moreover, cholesterol binds the synaptic
vesicle protein synaptophysin and modulates interaction with the
essential vesicular SNARE protein, synaptobrevin, to regulate
exocytosis [28]. Knockdown of SREBP-2 in primary neuronal
cultures produces decreases in expression of the synaptic vesicle
marker VAMP2 [9]. Interestingly, deletion of low-density
lipoprotein receptor-related protein 1 (LRP1) in forebrain neurons
in mice leads to a decrease in brain cholesterol levels and memory
loss with selective reduction of glutamate receptor subunits, which
is partially rescued by restoring neuronal cholesterol [29]. These
reports are consistent with the phenotypes of attenuated synapse
transmission and cognitive impairment with decreased synapto-
somal markers in N-Scap (+/2) mice.
Activation of glial cells, as demonstrated by increased GFAP
staining, is a common feature of many types of neural insults
including trauma, toxins, neurodegenerative triggers, or infection
[30]. Multiple studies have reported increased GFAP expression or
astrocyte content in cerebral cortices and hippocampi of diabetic
animal models [21,31,32]; however, the mechanisms producing
these changes have not been elucidated. The brains of N-Scap
(2/2) mice show increased GFAP expression and gliosis.
Whether this is a compensatory or reactive response induced by
cholesterol deficiency in the brain remains to be determined.
Several neurodegenerative diseases have been associated with
alterations in cholesterol metabolism. Reduction of cholesterol
synthesis in astrocytes is thought to contribute to neurodegener-
ation in multiple models of Huntington disease [33]. Alzheimer
disease has been associated with both diabetes and cholesterol
metabolism [34–37]. The e4 allele of ApoE, a cholesterol transport
protein, is the only known risk factor, other than aging, for late
onset Alzheimer disease [35]. On the other hand, studies
examining the relationship of serum cholesterol levels in the
elderly to dementia have differing conclusions, and several clinical
trials in humans using the statin class of lipid lowering drugs have
yielded conflicting results (reviewed in [36]). Part of this may
reflect the broad range of human physiology. For example, in our
previous study we showed a 3-fold range of expression of Srebf2
and Hmgcr and a 2-fold range in synaptosomal cholesterol content
in brains of 16 elderly humans with and without diabetes and
dementia [9]. Based on our studies and others [36], one might
predict that too much cholesterol, as well as too little, could have
detrimental effects on neuronal function. However, because
cholesterol in the brain is controlled independently of serum
cholesterol, we do not currently have a clinically useful tool for
assessing cholesterol levels in the human brain. Interestingly, a
recent study used intranasal delivery of insulin to the brain as a
therapy for human dementia patients with some improvement
seen in memory and self care tasks [38]. The source of this benefit
is unknown, but one of the responses to this therapy may be an
increase in cholesterol synthesis in the brain.
Taken together with our previous work [9] we propose a model
for how diabetes may affect cholesterol in the brain, leading to
changes in behavior and brain function (Figure 7). In this model,
diabetes mellitus reduces expression of SCAP in the brain, and this
reduction of SCAP causes a defect in SREBP-2 processing, leading
to a reduction in active SREBP-2. This leads to a down-regulation
of genes involved in brain cholesterol synthesis, which leads to
impaired synaptic transmission and abnormal cognitive function.
Figure 7. Proposed model for SCAP contribution to cognitive dysfunction and altered metabolism in diabetes. Diabetes reduces SCAP
and mature SREBP-2 in the brain resulting in a reduction of cholesterol synthesis and cerebral decrease in synaptosomal cholesterol. This causes a
decrease in normal synapse formation, altering synapse transmission, cerebral control of metabolism and various behaviors, including cognitive
function.
doi:10.1371/journal.pbio.1001532.g007
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regulation in the brain in diabetes, and open the possibility of
therapeutic strategies for reversing the effects of diabetes on the
brain and nervous system.
Materials and Methods
Animals
All animal studies followed the US National Institutes of Health
guidelines and were approved by the Institutional Animal Care
and Use Committees at the Joslin Diabetes Center and Beth Israel
Deaconess Medical Center.
Scap-floxed mice [10], nestin-Cre mice [11], C57BL/6 mice,
and db/db mice (C57Bl/Ks background) were purchased from the
Jackson Laboratory. Scap-floxed mice with the nestin-Cre transgene
were maintained on a C57BL/66129Sv mixed genetic back-
ground; therefore for all studies littermates were used for analysis.
For STZ-induced diabetes experiments, 7-wk-old C57BL/6 mice
were treated with a single intraperitoneal injection (200 mg/g body
weight) of STZ (Sigma). Some of the STZ diabetic mice were
treated ICV with insulin. For these experiments 7-wk-old C57Bl/6
mice were placed in a stereotactic device under anesthesia, and a
26-gauge guide cannula (Plastics One Inc) was inserted into the
right lateral cerebral ventricle (1.0 mm posterior, 1.0 mm lateral,
and 2.0 mm ventral to the bregma). A dummy stylet was inserted
into each cannula until used. After 1 wk of recovery, the mice
received a single IP injection of STZ to induce diabetes. Twelve
days later, the mice received three ICV injections of insulin (3 mU
in 2 ml) or the same volume of PBS (9am, 7pm, and 9am the
following day) through an internal cannula using a Hamilton
microsyringe. Four hours after the last injection the hypothalami
were collected. All mice were maintained on a 12-h light/12-h
dark cycle and fed a standard mouse chow diet (LabDiet Mouse
Diet 9 F, PMI Nutrition International). All mice used for
experiments were male. For analysis of gene and protein
expression, the brain was quickly removed under anesthesia with
2.5% Avertin (15 ml/g body weight, IP), placed on ice, and
dissected into the hypothalamus and cerebral cortex using a mouse
brain matrix (ASI Instruments Inc.).
RNA Extraction and Gene Expression Analysis by Real-
Time PCR
RNA from murine brain tissue was isolated using an RNeasy kit
(Qiagen). As a template, 1 mg of total RNA was reverse-
transcribed in 50 ml using a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems) according to the manufac-
turer’s instructions. Three microliters of diluted (1:4) reverse
transcription reaction was amplified with specific primers (300 nM
each) in a 25 ml PCR reaction with a SYBR Green PCR Master
Mix (Applied Biosystems). Analysis of gene expression was done in
the ABI PRISM 7000 sequence detector with initial denaturation
at 95uC for 10 min followed by 40 PCR cycles, each cycle
consisting of 95uC for 15 s and 60uC for 1 min, and SYBR green
fluorescence emissions were monitored after each cycle. For each
gene, mRNA expression was calculated relative to Tbp expression
as an internal control.
Immunohistochemistry
Brains were immersed in 4% paraformaldehyde (PFA) overnight
at 4uC then embedded in paraffin, and 8 mm coronal sections were
collected.Sectionsweredeparaffinizedandblockedwith aMouseIg
Blocking Reagent (M.O.M. Immunodetection kit, Vector Labora-
tories) containing avidin for 1 h, washed with PBS, treated with
M.O.M diluent for 5 min, and incubated with a mouse monoclonal
antibody recognizing GFAP (1:500, Millipore) and biotin solution
for 30 min at room temperature. After washing with PBS, the
sections were incubated with a biotinylated anti-mouse IgG
secondary antibody for 20 min. The samples were washed with
PBS, treated with a streptavidin/peroxidase complex reagent,
washed with PBS again, and stained with a VIP Substrate kit
(Vector Laboratories). Hematoxylin was used for counter-staining.
Immunoblotting
Nuclear and cytoplasmic extracts of brain tissue were prepared
per the manufacturer’s directions (NE-PER kit, Pierce). Whole
tissue extracts were prepared using RIPA buffer containing 1%
SDS and protease inhibitor cocktail (Sigma). Protein concentra-
tions were measured using a BCA assay (Pierce). Immunoblotting
was performed with antibodies against SCAP (Santa Cruz), b-
tubulin, CREB, fatty acid synthase, acetyl-CoA carboxylase (Cell
Signaling Technology), SQLE (ProteinTech), SREBP-1/SREBP-2
(gifts from Jay Horton and Guosheng Liang), STX1A and PSD95
(Abcam), and SYP and MBP (Millipore).
Cholesterol Triglyceride Content
Brain tissue was homogenized in 50 mM NaCl. Lipid fraction
was then extracted through multiple washes with a 2:1
chloroform:methanol solution. Samples were dried down with
10% triton-X 100/acetone. Cholesterol content was assayed by
enzymatic assay (Wako Chemicals). Triglycerides were measured
by colorimetric assay (Abnova).
In Vivo Cholesterol Synthesis in the Brain
Each anesthetized animal was injected intraperitoneally with 50
mCi of [
3H]water in 0.2 ml of PBS. One hour after injection
(which is a time long enough to reflect endogenous rates of
synthesis and short enough to avoid significant inter-organ
redistribution [39]), blood was collected by retro-orbital puncture,
and the [
3H]water specific activity in the plasma was measured.
The brain was removed, and the whole cerebrum (250–290 mg)
was saponified with 2.5 ml of 2.5 M KOH (75uC, 2 h). Sterol-
containing lipids were extracted with 10 ml hexane and 5 ml 80%
ethanol. Cholesterol was isolated by thin layer chromatography
(hexane:diethyl ether:glacial acetic acid=80:20:1), and the incor-
porated tracer was measured by a scintillation counter. The
synthesis rates were calculated as nmol of [
3H]water incorporated
into cholesterol per gram of tissue per hour.
Electrophysiology
Transverse hippocampal slices (400 mm) were prepared from the
brains of 4–6-wk-old male control or N-Scap (+/2) littermates that
were submerged in an ice-cold high sucrose solution containing (in
mM): 250 sucrose, 2.5 KCl, 1.24 NaH2PO4, 10 MgCl2, 10 glucose,
26 NaHCO3, 0.5 CaCl2 that was aerated with 95% O2/5% CO2.
Slices were then maintained at 30uC in artificial cerebrospinal fluid
(ACSF) containing (in mM): 124 NaCl, 2.5 KCl, 1.24 NaH2PO4,
1.3 MgCl2, 10 glucose, 26 NaHCO3, 2.5 CaCl2, and allowed to
recover for at least 1 h before being transferred to the recording
chamber for the start of experiments.
Voltage-clamp whole-cell recordings of mEPSC events at area
CA1 neurons were recorded at a holding potential of 265 mV in
the presence of 500 nM tetrodotoxin (TTX) using a glass
microelectrode (9–10 MV) filled with an internal pipette solution
containing (in mM): 137 K-gluconate, 2 KCl, 5 HEPES, 5
MgATP, 0.3 NaGTP, 10 creatine (290 mOsm/l [pH 7.4]).
fEPSPs were elicited by stimulating the Schaeffer collaterals
with a concentric bipolar electrode (FHC) and recorded with an
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stratum radiatum of area CA1. Baseline test stimuli were applied
once per min at a test stimulation intensity (0.1 ms pulse width)
adjusted to evoke fEPSP amplitudes that were 40% of maximal
size. Paired-pulse stimulation was elicited by two consecutive test
stimuli; the interpulse interval was varied from 50–200 ms, at
50 ms increments. LTP was induced by four trains of 100 Hz (1 s
train duration) elicited 5 min apart. fEPSPs were not monitored
between each high frequency train but were monitored with the
test stimuli for up to 120 min after the induction of LTP.
All recordings were acquired with a Multiclamp 700B amplifier
(Molecular Devices) via a Digidata 1440A (Molecular Devices)
digitizer interface then recorded with pCLAMP 10.2 software.
Offline analysis of mEPSCs and fEPSPs were performed with
MiniAnalysis (Synaptosoft) and Clampfit 10.2 (Molecular Devices),
respectively. Statistics and graphs were produced using Prism 5
(GraphPad Software). Statistical significance for mean comparisons
was determined by the unpaired Student’s t test at p,0.05. Data
were represented as mean 6 SEM, where appropriate, and n refers
to the number of hippocampal slices, unless indicated otherwise.
Novel Object Recognition Test
The novel object recognition test was performed as described
previously [40] with slight modifications. Mice were maintained in
group housing over the course of the experiment. Briefly, the mice
were habituated for 1 h to a plastic cage box on the first day. The
floor was covered with 1 cm of wood bedding. On the second day, a
familiarization trial was performed for 5 min, allowing each mouse to
explore the two identical objects (objects A and B) in the same box.
The two objects were placed along the long axis of the box. Mice
were filmed while exploring objects A and B and this was quantified
to ensure that the mice did not show preference for the object on one
side of the cage over the other. There was not a significant difference
between exploration of object A and object B. Then, the mouse was
removed from the trial box and placed in its home cage for 1 h. After
each exposure, the objects were wiped with 70% ethanol to eliminate
odor clues.One hour after the familiarization,each mouse was placed
in the box with one of the old objects (object A) and a new one (object
C). The position of object C was the same as object B in the
familiarization trial, and the time to explore them was again 5 min. A
mouse was considered to be engaging in exploratory behavior if the
animal touched the object with its forepaw or nose or sniffed at the
object within a distance of 1 cm. Activity was monitored and
calculated from a timed video of the experimental field. In a separate
cohort of mice both the old object (object A) and the new object
(object C) were presented to mice for 30 s to determine if one object
was more interesting to the mice than the other. There was no
difference in exploratory behavior between the two objects when
presented simultaneously.
Novelty-Suppressed Feeding Test
The novelty-suppressed feeding test was performed as described
previously [19] with slight modifications. Twenty-four hours
before the test, food was removed from the cages. At the time of
testing, a pair of food pellets (regular chow) were placed on a white
paper disk positioned in the center of a trial box without wood
bedding. An animal was placed in the corner. The latency to enter
the arena and then to chew the pellets were recorded within a
5 min period. Activity was monitored and calculated from a timed
video of the experimental field.
Elevated Open Platform Test
The elevated open platform test was performed as described
previously [18] with slight modifications. In brief, a transparent
glass cylinder (12 cm diameter, 21 cm high) was placed upside-
down and each mouse was positioned at the top (open platform).
Freezing behavior was defined as no movement, excluding
respiratory movement, while in a crouching posture. The duration
of freezing was the total amount of time that the animal showed
freezing. If the mouse slipped off the platform, it was immediately
placed back on the platform and the experiment was continued.
The mouse behavior on the elevated open platform was video
recorded for 5 min.
Morris Water Maze
During the acquisition phase mice were randomly dropped at
one of four points; N, S, E, or W. A hidden platform was located in
the southwest (SW) quadrant. Mice were given 1 min to find the
hidden platform and latency was recorded. Mice were led to the
hidden platform if they did not reach it within 1 min. Each mouse
went through eight trials per day. Latency times leveled off on day
4. On day 5 the probe trial was conducted. The hidden platform
was removed and the mouse was dropped off at the N drop point.
Time spent in each quadrant was recorded over 1 min. Data was
analyzed using TopScan software from Cleversys, Inc.
Contextual Fear Conditioning
On day one each mouse was placed in a novel box for 2 min
and freezing activity was recorded (baseline). At the end of the
2 min the mouse received a 0.5 mA shock for 2 s. Freezing time
was again measured over 2 min (post shock 1). At the end of the
2 min a second 0.5 mA shock was delivered over 2 s and freezing
was recorded for 1 min. The mouse was then returned to its home
cage. On day 2 each mouse was placed back in the cage from day
1 and freezing was recorded for 3 min (context). The mice were
then placed in an unfamiliar box and freezing was again measured
for 3 min (altered context). Data was analyzed using TopScan
software from Cleversys, Inc.
Statistical Analysis
Data are expressed as the mean 6 SEM. Statistical significance
was calculated using an unpaired Student’s t-test for comparison
between two groups, and by an analysis of variance (ANOVA) for
multigroup comparison. Fisher’s PLSD was used for the Morris
water maze and contextual fear conditioning.
Supporting Information
Figure S1 N-Scap (2/2) mice express less GFAP in the brain.
mRNA expression levels of Gfap (an astrocyte marker), Emr1 (a
microglia marker), and Mtap2 (a neuron marker) in the brains of
control, N-Scap (+/2), and N-Scap (2/2) mice. *, p,0.05;
**, p,0.01 by t-test.
(TIF)
Figure S2 SREBP-1 target proteins are significantly reduced in
N-Scap (2/2) mice. Western blots of whole cell lysates from P0
brains blotted for fatty acid synthase (FAS), acetyl-CoA carbox-
ylase (ACC) or b-tubulin.
(TIF)
Figure S3 There is no change in Cyp46a1 expression in N-Scap
(+/2)o rN -Scap (2/2) mice. mRNA expression levels of
Cyp46a1 in (A) cortex and hypothalamus from 5-wk-old mice and
(B) whole brain from P0 mice. None of the comparisons are
significant.
(TIF)
Figure S4 There is no difference between control and N-Scap
(+/2) in the Morris water maze. Mice were trained to the
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quadrant was recorded for the probe trial. Control mice spent
statistically more time and swam a greater distance in the SW
quadrant than all others (**). The N-Scap (+/2) mice spent more
time and swam a greater distance in the SW quadrant than the NE
and SE quadrants but not the NW quadrant (*).
(TIF)
Table S1 Body composition of N-Scap (+/2) mice is similar to
control. Body weight, lean mass, and fat mass were determined
from dual-energy X-ray absorptiometry (DEXA) scanning. Femur
lengths were measured from images generated by the DEXA scans
and scaled by 0.65 owing to enlargement of the images from the
DEXA scanning. Femur length is smaller in the N-Scap (+/2) mice
but body composition is unchanged.
(TIF)
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